Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Professor calls for better clinical trials of antivirals
Cats suffering from FIV and FeLV require special management and care.

Review looks at antiviral use in retrovirus-infected cats

A leading professor in small animal medicine is calling for better clinical trials of antivirals following publication of a review into their use in retrovirus-infected cats.

Professor Katrin Hartmann, head of the clinic of small animal medicine at the LMU University of Munich, Germany, says that more well-designed clinical trials would improve judgement on treatment efficacy and side effects.

Antiviral chemotherapy is of increasing interest in veterinary medicine, but is still not commonly used.  The review, published in the Journal of Feline Medicine and Surgery, examines current literature on antiviral chemotherapy in retrovirus-infected cats, focusing on drugs that are currently available on the market, and therefore could potentially be used in cats.

Concluding the review, Professor Hartmann writes: 'Unfortunately, the level of efficacy of antiviral chemotherapy is often poor and the duration of treatments used in clinical trials is often inappropriate for infections with such long clinical courses.

'Additionally, the degree of generalisability between experimental infections in cats kept under laboratory conditions and pet cats infected with field strains is unknown.
Therefore, it is very important that more well-designed double-blind, placebo-controlled trials using antivirals in naturally retrovirus-infected cats are undertaken to allow judgement on treatment efficacy and side effects of different antiviral compounds.'

Feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) are among the most common infections affecting cats worldwide, but differ in their potential to cause disease. 
Cats suffering from FIV and FeLV require special management and care and, provided they receive this, can live for many years in good health.

In more severe cases, the advice is to consider incorporating antivirals into the treatment regime. Most antivirals used in cats are licensed for humans and are specifically intended for treatment of human immunodeficiency virus (HIV), based on the rationale that FIV and HIV are closely related.

FeLV is not as closely related to HIV, with the result that the available drugs have mostly been found to be less effective against this retrovirus.

 

Become a member or log in to add this story to your CPD history

RCVS Knowledge appoints Veterinary Evidence editor-in-chief

News Story 1
 RCVS Knowledge has welcomed Professor Peter Cockcroft as editor-in-chief for Veterinary Evidence.

A world-renowned expert in evidence-based veterinary medicine, Prof Cockcroft will lead the strategic development and editorial quality of the open-access journal. He was previously in the role from 2017-2020.

Katie Mantell, CEO of RCVS Knowledge, said: "We are excited about the extensive knowledge of evidence-based veterinary medicine and clinical veterinary research that Peter brings, and we look forward to working with him over this next phase of the journal's development." 

Click here for more...
News Shorts
Defra to host bluetongue webinar for vets

The Department for Environment, Food and Rural Affairs (Defra) will be hosting a webinar for veterinary professional on bluetongue on Thursday, 25 April 2024.

Topics covered will include the transmission cycle, pathology and pathogenesis, clinical signs (including signs seen in recent BTV-3 cases in the Netherlands), and control and prevention.

The session, which will take place from 6pm to 7.30pm, is part of Defra's 'Plan, Prevent and Protect' webinar series, which are hosted by policy officials, epidemiologists and veterinary professionals from Defra and the Animal and Plant Health Agency. The bluetongue session will also feature insights from experts from The Pirbright Institute.

Those attending will have the opportunity to ask questions. Places on the webinar can be booked online.